News & Events
fineSA® to be used in astronaut study (03-2016)
Acuitas Medical is due to start an exciting pilot study with the National Aeronautics and Space Administration, NASA.
Acuitas technology wins Bevan Commission backing (01-2016)
Acuitas Medical and Consultant Spinal Surgeon Iona Collins are delighted to have won Welsh funding to enable a collaboration on a study of cancer patients at risk of metastatic spinal cord compression.
Acuitas presents at ASBMR (10-2015)
Acuitas Medical has presented a poster at the prestigious annual meeting of the American Society for Bone and Mineral Research (ASBMR) in collaboration with Colorado State University (CSU).
Acuitas to present at premier bone meeting (08-2015)
Acuitas Medical has been invited to present a poster at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting.
Acuitas Medical receives FDA clearance for fineSA® (06-2015)
Acuitas Medical Ltd has received market clearance from the United States Food and Drug Administration (FDA) for fineSA®
Quality assured until 2018 (03-2015)
Acuitas Medical Ltd has had its ISO 13485 accreditation confirmed until 2018, following an audit by BSI.
Acuitas achieves CE marking (03-2015)
Acuitas Medical Ltd is delighted to have been awarded CE marking, following an in depth appraisal by BSI.
Acuitas Medical publishes bone paper (12-2014)
Acuitas Medical is proud to have published in the journal Calcified Tissue International and Musculoskeletal Research.
Patient study successfully completed (08-2014)
Acuitas Medical has successfully completed a study at Swansea University to generate a normative reference set of fineSA® measurements in people expected to have reached peak bone mass.
Honour of second bone work invite (02-2014)
Amanda Davies has been invited for the second year running to give a presentation of the company′s bone work at the European Congress on Osteoporosis and Osteoarthritis, which will be held this year in Seville from April 2-5. The work is entitled: 'In vivo quantification of trabecular microarchitecture in the lumbar vertebrae of healthy volunteers by fineSA®: a magnetic resonance technique'.
Acuitas Medical and Fine Structure Analysis - fineSA®
Extending the limits of MRIThe mission of Acuitas Medical is the development and commercialisation of our unique magnetic resonance-based diagnostic technique, Fine Structure Analysis (fineSA®) for the in-vivo characterisation of the spacing of anatomical structure on a fine scale. Changes in anatomical structures are associated with the early stages of a number of diseases.
The company’s leadership team is based in Swansea, Wales, and between its members has decades of experience at the forefront of medical imaging. The company was founded in May 2006 and has to date been funded by a combination of private investments and grants.
Our patented software tools work as an add-on to existing magnetic resonance imaging hardware allowing the proprietary data to be acquired in as little as 16 seconds. The information is then analysed and returned as a report.
The company’s quality system and product has ISO13485 certification . The acquisition tool, analysis system and display are all protected by patent.
Acuitas Medical Ltd
8 Technium One, Kings Road, Swansea Waterfront , SA1 8PH, Wales, UK
